Skip to main content
Công ty Cổ phần Dược phẩm Imexpharm logo

Công ty Cổ phần Dược phẩm Imexpharm — Investor Relations & Filings

Ticker · IMP ISIN · VN000000IMP0 HSX Manufacturing
Open in API
Filings indexed 381 across all filing types
Latest filing 2026-01-30 Governance Information
Country VN Viet Nam
Listing HSX IMP

About Công ty Cổ phần Dược phẩm Imexpharm

www.imexpharm.com

Imexpharm Corporation is a prominent pharmaceutical company with over 48 years of experience in the manufacturing, compounding, and distribution of high-quality pharmaceutical products. The company operates extensive production facilities, including three EU-GMP certified factory clusters and one WHO-GMP certified cluster, making it a leader in EU-GMP compliant manufacturing. Imexpharm is recognized as a top producer of antibiotics and offers a diverse product portfolio encompassing injectable and oral antibiotics, cardiovascular, ophthalmic, musculoskeletal, respiratory, and digestive system treatments, alongside vitamins, minerals, and health protection foods. With 28 product registrations for 11 products in Europe, Imexpharm is dedicated to delivering effective and safe healthcare solutions to the community.

Recent filings

Filing Released Lang Actions
IMP: Báo cáo tình hình quản trị công ty năm 2025
Governance Information Classification · 91% confidence The document is titled “Báo cáo tình hình quản trị Công ty năm 2025” (Corporate Governance Report for the Year 2025) and contains detailed sections on governance model, General Meeting of Shareholders activities, Board of Directors structure, internal audit, etc. It is a standalone Corporate Governance Report rather than an announcement of filing, proxy materials, or an annual/quarterly financial report. This aligns with the definition of Governance Information (CGR).
2026-01-30 Vietnamese
IMP: CBTT thông qua ý kiến HĐQT về việc chào mua công khai đối với cổ phiếu IMP
M&A Activity Classification · 85% confidence The document is an “Extraordinary Information Disclosure” by Imexpharm Corporation concerning the Board of Directors’ approval of their opinion on a public tender offer for shares by LIAN SGP HOLDING PTE. LTD. It contains board resolutions and official letters specifically tied to a takeover bid (public tender offer). Under the filing definitions, such announcements are classified as M&A Activity (Code: TAR), since they relate directly to a third‐party takeover bid rather than a routine report or financing update.
2026-01-30 Vietnamese
IMP: Công văn của HĐQT về việc chậm đưa ra ý kiến đối với Hồ sơ CMCK của LIAN SGP HOLDING PTE.LTD
M&A Activity Classification · 82% confidence The document is an official extraordinary information disclosure by Imexpharm Corporation concerning the Board of Directors’ official letter on delaying its opinion in response to a public tender offer dossier from LIAN SGP HOLDING PTE. LTD. It is directly related to a takeover bid process and contains the full text of the BOD’s letter, including legal references, reasons for delay, and commitment on timing. This falls squarely under announcements and documents related to merger proposals or takeover bids, matching the M&A Activity category.
2026-01-23 Vietnamese
IMP: Giải trình biến động KQKD quý 4/2025 so với cùng kỳ năm trước
Regulatory Filings Classification · 87% confidence The document is an official regulatory disclosure addressed to the Securities State Commission of Vietnam and the Ho Chi Minh Stock Exchange explaining a greater-than-10% variance in quarterly business results. It is not a full financial report (like an annual or interim report), nor an earnings release, proxy statement, or dividend notice. It provides narrative and a table of Q4 results versus prior year and specific commentary on causes, fitting the catch-all category for miscellaneous regulatory filings. Therefore, it is classified as a Regulatory Filing (RNS).
2026-01-20 Vietnamese
IMP: Thông báo về việc nhận được hồ sơ chào mua công khai từ LIAN SGP Holding Pte. Ltd.
M&A Activity Classification · 90% confidence The document is a public disclosure by Imexpharm Corporation that it has received a public tender offer dossier from LIAN SGP HOLDING PTE. LTD., detailing the number of shares to be acquired (77.94% of charter capital), the tender price, and the securities agent. This is specifically an announcement of a takeover bid/tender offer, fitting the definition of M&A Activity (Code: TAR).
2026-01-15 Vietnamese
IMP: Nghị quyết HĐQT về việc thành lập Chi nhánh Cát Khánh
Board/Management Information Classification · 86% confidence The document is a public disclosure filed on the State Securities Commission and Ho Chi Minh Stock Exchange portals. It contains the full text of a Board of Directors’ resolution (No. 02/2026/NQ-HĐQT-IMP) regarding the establishment of a new branch (Cat Khanh Branch) of Imexpharm Corporation. This is corporate governance/management information about a board decision rather than a financial report, earnings release, or other regulatory form. Therefore, it fits the Board/Management Information (MANG) category.
2026-01-08 Vietnamese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.